FGF19 Gene Amplification clinical trials at UCSF
1 research study open to eligible people
FGF19 gene amplification occurs when the FGF19 gene makes more copies than usual. UCSF is studying the safety of a new drug called TYRA-430 to treat liver cancer and other tumors. These trials assess how well TYRA-430 works in patients with FGF/FGFR pathway changes.
Showing trials for
Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
open to eligible people ages 18 years and up
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
San Francisco, California and other locations
Last updated: